Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

CYLD-R324A inhibits ROCK. 2 / 2

| 2

➶

reach

"Because microtubule disruption has been linked to release of at least two Rho GEFs, Trio and RhoGEF-H1 (Birukova et al., 2006; Krendel et al., 2002; Mikelis et al., 2015; van Haren et al., 2014), whic[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

27681433

➶

reach

"Because microtubule disruption has been linked to release of at least two Rho GEFs, Trio and RhoGEF-H1, which subsequently activate ROCK, we sought to test whether the non cleavable R324A CYLD mutant can also suppress ROCK kinase activity following thrombin treatment."

27681433

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...